0001516513-23-000028.txt : 20230516 0001516513-23-000028.hdr.sgml : 20230516 20230516163516 ACCESSION NUMBER: 0001516513-23-000028 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230516 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230516 DATE AS OF CHANGE: 20230516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Doximity, Inc. CENTRAL INDEX KEY: 0001516513 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING SERVICES [7371] IRS NUMBER: 272485512 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40508 FILM NUMBER: 23928140 BUSINESS ADDRESS: STREET 1: 500 THIRD STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (650) 549-4330 MAIL ADDRESS: STREET 1: 500 THIRD STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 8-K 1 docs-20230516.htm 8-K docs-20230516
0001516513FALSE00015165132023-05-162023-05-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________________________________________
FORM 8-K
_________________________________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 16, 2023
_________________________________________________________________________________________________________________
Doximity, Inc.
(Exact Name of Registrant as Specified in Its Charter)
_________________________________________________________________________________________________________________
Delaware001-4050827-2485512
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
500 3rd St.
Suite 510
San Francisco, CA 94107
(Address of principal executive offices, including zip code)
(650) 549-4330
(Registrant's telephone number, including area code)
_______________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, $0.001 par value per shareDOCSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02 – Results of Operations and Financial Condition
On May 16, 2023, Doximity, Inc. (“Doximity”) issued a press release announcing its financial results for its fiscal quarter and year ended March 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.
The information provided in this Item 2.02 of this Current Report on Form 8-K, and the Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On May 16, 2023, Doximity announced the appointment of Craig Overpeck as Senior Vice President, Commercial Operations.
Mr. Overpeck, age 50, was previously the Chief Operating Officer for P\S\L Group from October 2020 to December 2022, a company that provides medical education, medical market research, and pharmaceutical industry information globally. Prior to that, Mr. Overpeck was the founder and served as the Chief Executive Officer of Science and Medicine Group (SMG) from August 2017 to September 2020. Starting in August 2000, Mr. Overpeck was Chief Technology Officer at MDLinx which was acquired in June 2006 by M3 where he also served as Chief Operating Officer for M3 USA until May 2017; in that role, Mr. Overpeck was responsible for the creation of M3 Global Research, linking M3's physician communities around the world from Asia to Europe to North America. Mr. Overpeck attended graduate school for Biology at Villanova University and holds a B.S. in Biology and Chemistry from Ursinus College.
There are no arrangements or understandings between Mr. Overpeck and any other persons pursuant to which he was appointed as the Senior Vice President, Commercial Operations of Doximity. There are no family relationships between Mr. Overpeck and any director, executive officer or any person nominated or chosen by Doximity to become a director or executive officer. No information is required to be disclosed with respect to Mr. Overpeck pursuant to Item 404(a) of Regulation S-K.
In connection with his appointment as Senior Vice President, Commercial Operations, on April 27, 2023, we entered into an offer letter with Mr. Overpeck (the “Offer Letter”). The Offer Letter provides for his at-will employment and sets forth his initial base salary of $300,000, an initial equity grant of restricted stock units of the Company’s Class A common stock (“RSUs”) valued at $4,000,000 on the grant date, to vest quarterly over four years, and another RSU grant valued at $4,000,000 on the grant date to vest in equal amounts annually over four years based on performance goals to be established each year. In addition, Mr. Overpeck is eligible to participate in our employee benefit health and welfare plans. Mr. Overpeck also entered into Doximity’s standard form of indemnification agreement.
The foregoing description of the Offer Letter is a summary and is qualified in its entirety by the text of the agreement, which will be filed as an exhibit to Doximity’s next annual report on Form 10-K.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
Exhibit NumberDescription
99.1
104Cover Page Interactive Data File (embedded within the inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 16, 2023
DOXIMITY, INC.
By:
/s/ Anna Bryson
Anna Bryson
Chief Financial Officer


EX-99.1 2 doximity-2023331xex991.htm EX-99.1 Document

Exhibit 99.1
Doximity Announces Fourth Quarter and Fiscal Year 2023 Financial Results and New Senior Leadership Hires
Q4 total revenues of $111.0 million, up 18% year-over-year
Q4 net income margin of 28% and adjusted EBITDA margin of 44%
Fiscal year 2023 total revenues of $419.1 million, up 22% year-over-year
Fiscal year 2023 net income margin of 27% and adjusted EBITDA margin of 44%

SAN FRANCISCO, Calif., May 16, 2023 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2023 fourth quarter and fiscal year ended March 31, 2023. The company also announced the appointment of two new senior leadership members, Craig Overpeck as SVP of commercial operations and Ben Greenberg as SVP of commercial products.
“With the public health emergency officially over, we’re proud to emerge with a record number of providers using our physician cloud in Q4 to power their scheduling, fax, e-signature, and telehealth needs,” said Jeff Tangney, co-founder and CEO at Doximity. “We’re also thrilled to welcome Craig Overpeck and Ben Greenberg to our senior leadership team, as we continue to grow and scale our commercial businesses.”
Mr. Overpeck joins Doximity with over 25 years of experience delivering digital solutions to serve and connect physicians. He served as the U.S. chief operating officer at M3 for over a decade, and spent more than 16 years as co-founder and chief technology officer at MDLinx.
Mr. Greenberg also joins Doximity with decades of experience building digital products. Most notably, he spent more than 11 years at WebMD / Medscape, where he served as vice president of mobile products and user experience.
Fiscal 2023 Fourth Quarter Financial Highlights
All comparisons, unless otherwise noted, are to the three months ended March 31, 2022.
Revenue: Revenue of $111.0 million, versus $93.7 million, an increase of 18% year-over-year.
Net income and non-GAAP net income: Net income of $30.7 million, versus $36.7 million, representing a margin of 27.6%, versus 39.2%. Non-GAAP net income of $42.1 million, versus $44.9 million, representing a margin of 38.0%, versus 47.9%.
Adjusted EBITDA: Adjusted EBITDA of $48.9 million, versus $39.4 million, an increase of 24% year-over-year, representing adjusted EBITDA margins of 44.1%, versus 42.0%.
Net income per share and non-GAAP net income per share: Diluted net income per share was $0.14, versus $0.17, while non-GAAP diluted net income per share was $0.20, versus $0.21.
Operating cash flow and free cash flow: Operating cash flow of $46.6 million, versus $47.0 million, a decrease of 1% year-over-year, and free cash flow of $45.6 million, versus $44.9 million, an increase of 2% year-over-year.
Fiscal Year 2023 Financial Highlights
All comparisons, unless otherwise noted, are to the fiscal year ended March 31, 2022.
Revenue: Revenue of $419.1 million, versus $343.5 million, an increase of 22% year-over-year.
Net income and non-GAAP net income: Net income of $112.8 million, versus $154.8 million, representing a margin of 26.9%, versus 45.1%. Non-GAAP net income of $154.9 million, versus $180.6 million, representing a margin of 37.0%, versus 52.6%.
Adjusted EBITDA: Adjusted EBITDA of $184.0 million, versus $150.3 million, an increase of 22% year-over-year, representing adjusted EBITDA margins of 43.9%, versus 43.7%.
Net income per share and non-GAAP net income per share: Diluted net income per share was $0.53, versus $0.70, while non-GAAP diluted net income per share was $0.73, versus $0.82.
Operating cash flow and free cash flow: Operating cash flow of $179.6 million, versus $126.6 million, an increase of 42% year-over-year, and free cash flow of $173.4 million, versus $120.9 million, an increase of 43% year-over-year.
1


Financial Outlook
Doximity is providing guidance for its fiscal first quarter ending June 30, 2023 as follows:
Revenue between $106.5 million and $107.5 million.
Adjusted EBITDA between $39.0 million and $40.0 million.
Doximity is providing guidance for its fiscal year ending March 31, 2024 as follows:
Revenue between $500 million and $506 million.
Adjusted EBITDA between $216 million and $222 million.
2


Conference Call Information
Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The Company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. For more information, visit www.doximity.com.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty, including the resurgence or resolution of the COVID-19 pandemic or other pandemics, epidemics or infectious diseases; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in the Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022. Additional information will be provided in our Annual Report on Form 10-K for the annual period ended March 31, 2023. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations Contact:
Perry Gold
ir@doximity.com
Media Contact:
Amanda Cox
pr@doximity.com




3


DOXIMITY, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
March 31, 2023March 31, 2022
Assets
Current assets:
Cash and cash equivalents$158,027 $112,809 
Marketable securities682,972 685,304 
Accounts receivable, net 107,047 81,073 
Prepaid expenses and other current assets22,289 19,439 
Deferred contract costs, current5,118 5,512 
Total current assets975,453 904,137 
Property and equipment, net11,279 8,488 
Deferred income tax assets34,907 48,558 
Operating lease right-of-use assets13,819 1,087 
Intangible assets, net31,836 7,909 
Goodwill67,940 18,915 
Other assets1,654 2,263 
Total assets$1,136,888 $991,357 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$1,272 $463 
Accrued expenses and other current liabilities31,245 25,270 
Deferred revenue, current105,238 84,907 
Operating lease liabilities, current1,752 642 
Total current liabilities139,507 111,282 
Deferred revenue, non-current198 78 
Operating lease liabilities, non-current13,885 447 
Contingent earn-out consideration liability, non-current15,942 — 
Other liabilities, non-current1,240 956 
Total liabilities170,772 112,763 
Stockholders' Equity
Preferred stock— — 
Common stock194 192 
Additional paid-in capital762,150 702,589 
Accumulated other comprehensive loss(14,083)(15,294)
Retained earnings217,855 191,107 
Total stockholders' equity966,116 878,594 
Total liabilities and stockholders’ equity$1,136,888 $991,357 

4


DOXIMITY, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended March 31,Fiscal Year Ended March 31,
2023202220232022
Revenue$110,966 $93,653 $419,052 $343,548 
Cost of revenue(1)
13,677 11,765 53,490 39,787 
Gross profit97,289 81,888 365,562 303,761 
Operating expenses(1):
Research and development21,541 17,424 80,186 62,350 
Sales and marketing33,148 25,899 123,523 92,129 
General and administrative9,759 10,644 36,745 35,746 
Total operating expenses64,448 53,967 240,454 190,225 
Income from operations32,841 27,921 125,108 113,536 
Other income (expense), net3,875 (16)8,048 469 
Income before income taxes36,716 27,905 133,156 114,005 
Provision for (benefit from) income taxes6,048 (8,821)20,338 (40,778)
Net income$30,668 $36,726 $112,818 $154,783 
Undistributed earnings attributable to participating securities— — — (21,526)
Net income attributable to Class A and Class B common stockholders, basic and diluted$30,668 $36,726 $112,818 $133,257 
Net income per share attributable to Class A and Class B common stockholders:
Basic$0.16 $0.19 $0.58 $0.82 
Diluted$0.14 $0.17 $0.53 $0.70 
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:
Basic193,829 191,579 193,176 163,484 
Diluted212,742 215,862 213,425 191,017 
(1) Costs and expenses include stock-based compensation expense as follows (in thousands):
Three Months Ended March 31,Fiscal Year Ended March 31,
2023202220232022
Cost of revenue$2,425 $2,006 $9,634 $4,979 
Research and development3,167 2,201 12,583 7,065 
Sales and marketing5,027 2,533 16,939 8,108 
General and administrative2,372 3,069 8,678 11,290 
Total stock-based compensation expense$12,991 $9,809 $47,834 $31,442 
5


DOXIMITY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months Ended March 31,Fiscal Year Ended March 31,
2023202220232022
Cash flows from operating activities
Net income$30,668 $36,726 $112,818 $154,783 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization2,708 1,368 10,283 5,040 
Deferred income taxes3,834 (9,275)13,226 (41,247)
Stock-based compensation, net of amounts capitalized12,991 9,809 47,834 31,442 
Non-cash lease expense537 302 2,027 1,159 
Amortization (accretion) of premium (discount) on marketable securities, net(29)1,469 3,115 4,332 
Loss on sale of marketable securities— 708 1,093 1,231 
Amortization of deferred contract costs2,428 2,389 8,785 9,755 
Other657 288 1,454 410 
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable(32,433)(11,439)(26,242)(31,017)
Prepaid expenses and other assets(5,372)(2,086)(3,448)(9,089)
Deferred contract costs(2,053)(2,937)(8,462)(9,609)
Accounts payable, accrued expenses and other liabilities(2,918)571 (195)8,664 
Deferred revenue35,625 19,367 17,527 1,828 
Operating lease liabilities(4)(296)(213)(1,107)
Net cash provided by operating activities46,639 46,964 179,602 126,575 
Cash flows from investing activities
Cash paid for acquisition— — (53,500)— 
Purchases of property and equipment(21)(1,060)(1,701)(1,912)
Internal-use software development costs(1,005)(1,049)(4,483)(3,785)
Purchases of marketable securities(60,303)(45,278)(190,560)(1,317,193)
Maturities of marketable securities48,125 6,302 83,139 47,919 
Sales of marketable securities— 16,864 107,182 633,802 
Other— 595 — 595 
Net cash used in investing activities(13,204)(23,626)(59,923)(640,574)
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering after deducting underwriting discounts and commissions— — — 553,905 
Proceeds from issuance of common stock upon exercise of stock options and common stock warrants2,471 3,378 9,926 12,612 
Proceeds from issuance of common stock in connection with the employee stock purchase plan2,418 1,395 4,759 1,395 
Taxes paid related to net share settlement of equity awards(1,469)(381)(3,822)(817)
Repurchase of common stock(15,282)— (85,324)(2,698)
Payments of deferred offering costs— — — (3,982)
Net cash provided by (used in) financing activities(11,862)4,392 (74,461)560,415 
Net increase in cash and cash equivalents21,573 27,730 45,218 46,416 
Cash and cash equivalents, beginning of period136,454 85,079 112,809 66,393 
Cash and cash equivalents, end of period
$158,027 $112,809 $158,027 $112,809 

6


Non-GAAP Financial Measures
To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:
Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, change in fair value of contingent earn-out consideration liability, and expenses associated with acquisitions from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.
We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.
Key Business Metrics1
Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
Customers with trailing 12-month subscription revenue greater than $100,000 and $10 million: The number of customers with TTM subscription revenue greater than $100,000 and $10 million is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $100,000 and $10 million in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.
1 The metric excludes the impact of the AMiON acquisition, which closed on April 1, 2022, including customers of, and subscription revenue generated from, the AMiON on-call scheduling and messaging application, and the impact of such acquisition was immaterial to the periods presented.
7


Reconciliation of GAAP to Non-GAAP Financial Measures
The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:
Three Months Ended March 31,Fiscal Year Ended March 31,
2023202220232022
(unaudited)
(in thousands, except percentages)
Net income$30,668 $36,726 $112,818 $154,783 
Adjusted to exclude the following:
Acquisition and other related expenses— 254 30 254 
Stock-based compensation12,991 9,809 47,834 31,442 
Depreciation and amortization2,708 1,368 10,283 5,040 
Provision for (benefit from) income taxes6,048 (8,821)20,338 (40,778)
Change in fair value of contingent earn-out consideration liability405 — 728 — 
Other income (expense), net(3,875)16 (8,048)(469)
Adjusted EBITDA$48,945 $39,352 $183,983 $150,272 
Revenue$110,966 $93,653 $419,052 $343,548 
Net income margin27.6 %39.2 %26.9 %45.1 %
Adjusted EBITDA margin44.1 %42.0 %43.9 %43.7 %

Three Months Ended March 31,Fiscal Year Ended March 31,
2023202220232022
(unaudited)
(in thousands)
Net cash provided by operating activities$46,639 $46,964 $179,602 $126,575 
Purchases of property and equipment(21)(1,060)(1,701)(1,912)
Internal-use software development costs(1,005)(1,049)(4,483)(3,785)
Free cash flow$45,613 $44,855 $173,418 $120,878 
Other cash flow components:
Net cash used in investing activities$(13,204)$(23,626)$(59,923)$(640,574)
Net cash provided by (used in) financing activities$(11,862)$4,392 $(74,461)$560,415 
8


Three Months Ended March 31,Fiscal Year Ended March 31,
2023202220232022
(unaudited)
(in thousands, except per share data and percentages)
GAAP cost of revenue$13,677 $11,765 $53,490 $39,787 
Adjusted to exclude the following:
Stock-based compensation(2,425)(2,006)(9,634)(4,979)
Amortization of acquired intangibles(137)— (548)— 
Non-GAAP cost of revenue$11,115 $9,759 $43,308 $34,808 
GAAP gross profit$97,289 $81,888 $365,562 $303,761 
Adjusted to exclude the following:
Stock-based compensation2,425 2,006 9,634 4,979 
Amortization of acquired intangibles137 — 548 — 
Non-GAAP gross profit$99,851 $83,894 $375,744 $308,740 
GAAP gross margin87.7 %87.4 %87.2 %88.4 %
Non-GAAP gross margin90.0 %89.6 %89.7 %89.9 %
GAAP research and development expense$21,541 $17,424 $80,186 $62,350 
Adjusted to exclude the following:
Stock-based compensation(3,167)(2,201)(12,583)(7,065)
Non-GAAP research and development expense$18,374 $15,223 $67,603 $55,285 
GAAP sales and marketing expense$33,148 $25,899 $123,523 $92,129 
Adjusted to exclude the following:
Stock-based compensation(5,027)(2,533)(16,939)(8,108)
Amortization of acquired intangibles(979)(252)(4,164)(1,046)
Change in fair value of contingent earn-out consideration liability(405)— (728)— 
Non-GAAP sales and marketing expense$26,737 $23,114 $101,692 $82,975 
GAAP general and administrative expense$9,759 $10,644 $36,745 $35,746 
Adjusted to exclude the following:
Acquisition and other related expenses— (254)(30)(254)
Stock-based compensation(2,372)(3,069)(8,678)(11,290)
Non-GAAP general and administrative expense$7,387 $7,321 $28,037 $24,202 
GAAP operating expense$64,448 $53,967 $240,454 $190,225 
Adjusted to exclude the following:
Acquisition and other related expenses— (254)(30)(254)
Stock-based compensation(10,566)(7,803)(38,200)(26,463)
Amortization of acquired intangibles(979)(252)(4,164)(1,046)
Change in fair value of contingent earn-out consideration liability(405)— (728)— 
Non-GAAP operating expense$52,498 $45,658 $197,332 $162,462 
9


Three Months Ended March 31,Fiscal Year Ended March 31,
2023202220232022
(unaudited)
(in thousands, except per share data and percentages)
GAAP operating income$32,841 $27,921 $125,108 $113,536 
Adjusted to exclude the following:
Acquisition and other related expenses— 254 30 254 
Stock-based compensation12,991 9,809 47,834 31,442 
Amortization of acquired intangibles1,116 252 4,712 1,046 
Change in fair value of contingent earn-out consideration liability405 — 728 — 
Non-GAAP operating income$47,353 $38,236 $178,412 $146,278 
GAAP net income$30,668 $36,726 $112,818 $154,783 
Adjusted to exclude the following:
Acquisition and other related expenses— 254 30 254 
Stock-based compensation12,991 9,809 47,834 31,442 
Amortization of acquired intangibles1,116 252 4,712 1,046 
Change in fair value of contingent earn-out consideration liability405 — 728 — 
Income tax effect of non-GAAP adjustments (1)
(3,048)(2,166)(11,194)(6,876)
Non-GAAP net income$42,132 $44,875 $154,928 $180,649 
Non-GAAP net income margin38.0 %47.9 %37.0 %52.6 %
GAAP undistributed earnings attributable to participating securities$— $— $— $(21,526)
Impact on undistributed earnings attributable to participating securities due to non-GAAP adjustments— — — (2,616)
Non-GAAP undistributed earnings attributable to participating securities$— $— $— $(24,142)
Non-GAAP net income$42,132 $44,875 $154,928 $180,649 
Non-GAAP undistributed earnings attributable to participating securities— — — (24,142)
Non-GAAP net income attributable to Class A and Class B stockholders, basic and diluted$42,132 $44,875 $154,928 $156,507 
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:
Basic193,829 191,579 193,176 163,484 
Diluted212,742 215,862 213,425 191,017 
Non-GAAP net income per share attributable to Class A and Class B stockholders:
Basic$0.22 $0.23 $0.80 $0.96 
Diluted$0.20 $0.21 $0.73 $0.82 
(1) For the three months and fiscal years ended March 31, 2023 and 2022, management used an estimated annual effective non-GAAP tax rate of 21.0%.
10
EX-101.SCH 3 docs-20230516.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 docs-20230516_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 docs-20230516_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 16, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 16, 2023
Entity Registrant Name Doximity, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40508
Entity Tax Identification Number 27-2485512
Entity Address, Address Line One 500 3rd St.
Entity Address, Address Line Two Suite 510
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94107
City Area Code 650
Local Phone Number 549-4330
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, $0.001 par value per share
Trading Symbol DOCS
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0001516513
Amendment Flag false
XML 7 docs-20230516_htm.xml IDEA: XBRL DOCUMENT 0001516513 2023-05-16 2023-05-16 0001516513 false 8-K 2023-05-16 Doximity, Inc. DE 001-40508 27-2485512 500 3rd St. Suite 510 San Francisco CA 94107 650 549-4330 false false false false Class A common stock, $0.001 par value per share DOCS NYSE false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.doximity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports docs-20230516.htm docs-20230516.xsd docs-20230516_lab.xml docs-20230516_pre.xml doximity-2023331xex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "docs-20230516.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "docs-20230516.htm" ] }, "labelLink": { "local": [ "docs-20230516_lab.xml" ] }, "presentationLink": { "local": [ "docs-20230516_pre.xml" ] }, "schema": { "local": [ "docs-20230516.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "docs", "nsuri": "http://www.doximity.com/20230516", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "docs-20230516.htm", "contextRef": "i18c33f40d03e4a5198c7ba0d367cac08_D20230516-20230516", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.doximity.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "docs-20230516.htm", "contextRef": "i18c33f40d03e4a5198c7ba0d367cac08_D20230516-20230516", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001516513-23-000028-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001516513-23-000028-xbrl.zip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end